Viking Therapeutics, Inc. (NASDAQ:VKTX)‘s stock had its “buy” rating reaffirmed by equities researchers at Maxim Group in a report released on Monday. They presently have a $5.00 target price on the biotechnology company’s stock. Maxim Group’s target price indicates a potential upside of 296.83% from the stock’s current price.
The analysts wrote, “Viking announced additional positive data for VK2809 in animal models of NASH demonstrating that VK2809 changes the expression of key genes associated with the disease’s development and progression.””
VKTX has been the subject of a number of other reports. ValuEngine upgraded Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. HC Wainwright restated a “buy” rating and set a $7.00 price objective (up from $5.00) on shares of Viking Therapeutics in a research report on Monday, July 17th.
Viking Therapeutics (VKTX) opened at 1.26 on Monday. The stock’s 50 day moving average price is $1.16 and its 200 day moving average price is $1.44. The firm’s market capitalization is $34.90 million. Viking Therapeutics has a 52-week low of $0.90 and a 52-week high of $1.70.
Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). On average, equities analysts anticipate that Viking Therapeutics will post ($0.82) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/2887706/viking-therapeutics-inc-vktx-stock-rating-reaffirmed-by-maxim-group.html.
A hedge fund recently raised its stake in Viking Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 62.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 265,800 shares of the biotechnology company’s stock after purchasing an additional 102,600 shares during the period. Renaissance Technologies LLC owned approximately 1.12% of Viking Therapeutics worth $388,000 at the end of the most recent quarter. 5.67% of the stock is owned by institutional investors.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.